- 14% increase in revenue from the prior year third quarter - 50% increase in gross margin to 45% in the quarter from the prior year third quarter
- Net loss of $6.1 million, or $0.05 per share in the quarter compared to $28.1 million, or $0.24 in the prior year third quarter - Cash used in operating activities of $3.8 million, down from $21.9 million in the prior year third quarter SAN DIEGO , Nov.
Illumina, Inc. (NASDAQ: ILMN) and Sequenom, Inc. (NASDAQ: SQNM) today
announced they have agreed to settle all pending infringement claims and
other disputes between Sequenom and Verinata Health, Inc. The parties
will pool their owned and in-licensed intellectual property directed to
noninvasive prenatal testing (NIPT), including patents that will remain
the subject of ongoing interference proceedings.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.